David Morton Fox - 18 Mar 2026 Form 3 Insider Report for MediWound Ltd. (MDWD)

Role
Director
Signature
/s/ Yaron Meyer, attorney-in-fact
Issuer symbol
MDWD
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 17:31:49 UTC
Previous filing
20 Sep 2021
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fox David Morton Director C/O MEDIWOUND LTD., 42 HAYARKON STREET, YAVNE, ISRAEL /s/ Yaron Meyer, attorney-in-fact 18 Mar 2026 0001829578

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MDWD Ordinary shares 18,746 18 Mar 2026 Direct
holding MDWD Ordinary shares 750 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MDWD Series A Warrants 18 Mar 2026 Ordinary shares 6,534 $13.48 Direct
holding MDWD Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 14,285 $12.25 Direct
holding MDWD Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 1,607 $37.52 Direct
holding MDWD Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 5,357 $14.42 Direct
holding MDWD Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 5,900 $11.88 Direct
holding MDWD Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 7,542 $12.73 Direct
holding MDWD Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 5,600 $18.54 Direct
holding MDWD Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 6,250 $17.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
F2 The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.